Bristol Myers Squibb has partnered with the Cancer Research Institute and the Parker Institute for Cancer Immunotherapy in a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. (Press release)